Delivery of Rivaxan to the National Health System of the Republic of Cuba

Mon-Thu: 8: 30-17: 15
Fri: 8: 30-16: 00
Lunch: 12: 00-12: 30
Sat, Sun: closed

On August 2, the Institute of Hematology and Immunology received samples of the first batch of Rivaxan, a drug used to treat patients with bleeding disorders. This is the product of a strategic alliance between MedSol Cuba Laboratories and the State Enterprise ACADEMPHARM. The event was attended by the leadership of MedSol Cuba Laboratories and BioCubaFarmaSA.